Treatment options for primary cutaneous T-cell lymphoma
- Author:
- No author available
- Journal Title:
- International Journal of Dermatology and Venereology
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.1673-4173.2014.05.006
- Key Word:
- 淋巴瘤,T细胞,皮肤;治疗应用;Lymphoma,T-cell,cutaneous;Therapeutic uses
Abstract： Primary cutaneous T-cell lymphoma (CTCL) represents a group of diseases characterized by the abnormal proliferation of lymphocytes derived from the skin,with mycosis fungoides (MF) as the most common type.The choice of treatment for CTCL is mainly based on the tumor-node-metastasis-blood (TNMB) classification and staging system for cutaneous lymphomas proposed by the International Society for Cutaneous Lymphomas (ISCL)-World Health Organization-European Organization for Research and Treatment of Cancer (EORTC) in 2007.Other factors to be considered should include the time to onset of action and duration of sustained remission,as well as tolerability,side effects,convenience and cost of treatment.Supportive and local therapies are recommended for early CTCL,while systemic chemotherapy,with or without immunomodulatory therapy,is recommended for advanced CTCL.Some specific cytokines,monoclonal antibodies,and fusion toxins have been tried to treat CTCL.
- [1]Jeanette, Lundin,Hans, Hagberg,Roland, Repp,etc.Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome.[J].2003,101(11).
- [2]H S, Zackheim,M, Kashani-Sabet,S, Amin.Topical corticosteroids for mycosis fungoides. Experience in 79 patients.[J].1998,134(8).
- [3]Worel N.,Leitner G..Clinical Results of Extracorporeal Photopheresis[J].2012,39(4).
- [4]Onida F,Sureda A,Arranz R,etc.Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.[J].2010,28(29).
- [5]Edstrom DW,Ros AM,Porwit A.Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response.[J].2001,81(3).
- [6]Gurioli,C.,Neri,I.,D'Acunto,C..Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB[J].2010,21(1).
- [7]E, Goujon,G, Truc,T, Pétrella,etc.[Total skin electron beam therapy for early-stage mycosis fungoides: immediate results and long-term follow-up in 68 patients].[J].2009,136(3).
- [8]Jidar K,Ingen Housz Oro S,Beylot Barry M.Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases.[J].2009,161(3).
- [9]Alain H Rook,Timothy M Kuzel,Elise A Olsen.Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2[J].2003,17(6).
- [10]Daniel Walker,Heidi Jacobe.Phototherapy in the age of biologics.[J].2011,30(4).
- [11]Lyseng Williamson KA,Yang LP.Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.[J].2012,13(1).
- [12]Zaja,F.,Baldini,L.,Ferreri,A.J.M.,etc.Bendamustine salvage therapy for T cell neoplasms[J].2013,92(9).
- [13]Piccinno,R.,Caccialanza,M.,?uka,E.,etc.Localized conventional radiotherapy in the treatment of Mycosis Fungoides: Our experience in 100 patients[J].2014,28(8).
- [14]Bloom Tara,Kuzel Timothy M.,Querfeld Christiane,etc.Cutaneous T-Cell Lymphomas: A Review of New Discoveries and Treatments[J].2012,13(1).
- [15]Elma D Baron,Yoojin Lee.Photodynamic therapy: current evidence and applications in dermatology.[J].2011,30(4).
- [16]Elise, Olsen,Eric, Vonderheid,Nicola, Pimpinelli,etc.Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Ca[J].2007,110(6).
- [17]Hespel A,Mejdoubi Charef N,Yous S,etc.Interactions of bexarotene (LGD1069, Targretin) with the coagulation system.[J].2011,68(4).
- [18]V, Nikolaou,M P, Siakantaris,T P, Vassilakopoulos,etc.PUVA plus interferon α2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series.[J].2011,25(3).
- [19]Wollina,U..Cutaneous Tcell lymphoma: Update on treatment[J].2012,51(9).
- [20]Iwamoto,M.,Friedman,E.J.,Sandhu,P.,etc.Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor[J].2013,72(3).
- [21]Hamlin P,Horwitz S,O'Connor OA.Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.[J].2009,27(26).
- [22]Laetsch B,Dummer R,Cozzio A,etc.Standard and experimental therapy in cutaneous T-cell lymphomas.[J].2006,33(Suppl.1).
- [23]Burack LH,Ozawa M,Ferenczi K,etc.312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions.[J].1999,189(4).